## Update of the declaration of Declaration of Conformity pursuant to Section 161 of the German Stock Corporation Act (AktG)

In addition to the last Declaration of Conformity issued in November 2022 in accordance with Section 161 of the German Stock Corporation Act, the Management Board and Supervisory Board of MEDICLIN Aktiengesellschaft (MEDICLIN AG) declare the following with regard to the recommendations of the German Corporate Governance Code in the version of April 28, 2022 (DCGK 2022):

On the occasion of the initial appointment of Mr. Thomas Piefke as Chief Operating Officer (COO) of MEDICLIN AG with effect from October 1, 2023, for a term of office of five years, Recommendation B.3 DCGK 2022 is not complied with. According to this recommendation, initial appointments of Management Board members should be made for a maximum of three years.

The Supervisory Board is of the opinion that an appointment of the new Management Board member for the maximum term of five years permitted under stock corporation law is in the Company's best interest in this specific case and, in particular, will make an important contribution to the continuity of work on the Management Board of MEDICLIN AG in the coming years. Due to Mr. Thomas Piefke's previous many years of management activity in the Asklepios Group, the Supervisory Board also has no doubts that Mr. Thomas Piefke is a suitable candidate for the position of COO and has the necessary skills and experience. In the view of the Supervisory Board, the appointment of Mr. Thomas Piefke for a full term of office of five years was therefore preferable, so that it decided to declare a deviation from recommendation B.3 DCGK 2022.

Offenburg, September 21, 2023 MEDICLIN Aktiengesellschaft

The Supervisory Board

Offenburg, 21. September 2023

Update of the Declaration of conformity Sept 2023